Toxoplasmosis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
Toxoplasmosis Pipeline Drugs Market Report Overview
Toxoplasmosis is a disease that results from infection with the Toxoplasma gondii parasite. Symptoms include body aches, swollen lymph nodes, headache, fever, and fatigue. Risk factors include HIV/AIDS, chemotherapy, and immunosuppressant drugs. Treatment includes an antimalarial drug and antibiotics.
The toxoplasmosis pipeline products market research report provides comprehensive information on the therapeutics under development for toxoplasmosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for toxoplasmosis and features dormant and discontinued projects.
Toxoplasmosis Pipeline Products Market Segmentation by Targets
The key targets in the toxoplasmosis pipeline products market are calcium dependent protein kinase 1 and dihydrofolate reductase.
Toxoplasmosis Pipeline Products Market Analysis by Targets
For more target insights into the toxoplasmosis pipeline products market, download a free report sample
Toxoplasmosis Pipeline Products Market Segmentation by Mechanisms of Action
The key mechanisms of action in the toxoplasmosis pipeline products market are calcium dependent protein kinase 1 inhibitor and dihydrofolate reductase inhibitor.
Toxoplasmosis Pipeline Products Market Analysis by Mechanisms of Action
For more MoA insights into the toxoplasmosis pipeline products market, download a free report sample
Toxoplasmosis Pipeline Products Market Segmentation by Routes of Administration
The key routes of administration in the toxoplasmosis pipeline products market are oral, intramuscular, intravitreal, and nasal. Oral accounted for the highest number of toxoplasmosis drugs in development in terms of RoA, in 2022.
Toxoplasmosis Pipeline Products Market Analysis by Routes of Administration
For more RoA insights into the toxoplasmosis pipeline products market, download a free report sample
Toxoplasmosis Pipeline Products Market Segmentation by Molecule Types
The key molecule types in the toxoplasmosis pipeline products market are small molecule, live attenuated vaccine, monoclonal antibody, mRNA vaccine, recombinant vector vaccine, and subunit vaccine. The small molecule is the leading molecule type in the toxoplasmosis pipeline products market.
Toxoplasmosis Pipeline Products Market Analysis by Molecule Types
For more molecule type insights into the toxoplasmosis pipeline products market, downloahttps://www.globaldata.com/store/talk-to-us/?report=3169199d a free report sample
Toxoplasmosis Pipeline Products Market - Competitive Landscape
Some of the leading companies in the toxoplasmosis pipeline products market are AbbVie Inc, GSK plc, PGTx Ltd, Tiba Biotech LLC, and Vaxinano SE.
Toxoplasmosis Pipeline Products Market Analysis by Companies
To know more about the leading toxoplasmosis pipeline products market players, download a free report sample
Toxoplasmosis Pipeline Products Market Overview
Key Targets | Calcium Dependent Protein Kinase 1 and Dihydrofolate Reductase |
Key MoA | Calcium Dependent Protein Kinase 1 Inhibitor and Dihydrofolate Reductase Inhibitor |
Key RoA | Oral, Intramuscular, Intravitreal, and Nasal |
Key Molecule Type | Small Molecule, Live Attenuated Vaccine, Monoclonal Antibody, mRNA Vaccine, Recombinant Vector Vaccine, and Subunit Vaccine |
Leading Companies | AbbVie Inc, GSK plc, PGTx Ltd, Tiba Biotech LLC, and Vaxinano SE |
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of toxoplasmosis.
- The pipeline guide reviews pipeline therapeutics for toxoplasmosis by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration to discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in toxoplasmosis therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates toxoplasmosis therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA), and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews the latest news related to pipeline therapeutics for toxoplasmosis
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolios and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for toxoplasmosis.
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and their most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding the toxoplasmosis pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from the pipeline.
Table of Contents
Table
Figures
Frequently asked questions
-
What are the key targets in the toxoplasmosis pipeline products market?
The key targets in the toxoplasmosis pipeline products market are calcium dependent protein kinase 1 and dihydrofolate reductase.
-
What are the key mechanisms of action in the toxoplasmosis pipeline products market?
The key MoA in the toxoplasmosis pipeline products market are calcium dependent protein kinase 1 inhibitor and dihydrofolate reductase inhibitor.
-
What are the key routes of administration in the toxoplasmosis pipeline products market?
The key RoA in the toxoplasmosis pipeline products market are oral, intramuscular, intravitreal, and nasal.
-
What are the key molecule types in the toxoplasmosis pipeline products market?
The key molecule types in the toxoplasmosis pipeline products market are small molecule, live attenuated vaccine, monoclonal antibody, mRNA vaccine, recombinant vector vaccine, and subunit vaccine.
-
Which are the leading companies in the toxoplasmosis pipeline products market?
Some of the leading companies in the toxoplasmosis pipeline products market are AbbVie Inc, GSK plc, PGTx Ltd, Tiba Biotech LLC, and Vaxinano SE.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.